Estrella Immunopharma announced on June 3, 2025, that it entered into a securities purchase agreement on May 30, 2025, for a private investment in public equity (PIPE) financing. This financing is expected to result in approximately $3.35 million in gross proceeds for the company.
This equity raise provides crucial capital for Estrella, a clinical-stage biopharmaceutical company. The funds are essential to support its ongoing research and development activities, particularly the STARLIGHT-1 clinical trial.
The financing helps address the company's immediate liquidity needs and strengthens its financial position. It enables continued progress in the development of its CD19 and CD22-targeted ARTEMIS® T-cell therapies.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.